Neuralstem gets FDA approval for NSI-189 trial
NSI-189 is a proprietary new chemical entity discovered by Neuralstem that stimulates new neuron growth in the hippocampus.Neuralstem president and CEO Richard Garr said that the commencement of
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.
Initial shipments of pre-mixed Sucanon from Canada have already commenced, totaling five (5) containers – the equivalent of 6,000,000 tablets or 100,000 one-month patient supplies. Fero Industries has